NextCure (NXTC) Competitors $0.33 +0.00 (+0.63%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NXTC vs. SKYE, TNYA, IMMX, OKUR, ANEB, AADI, RPTX, CUE, ITRM, and ATNMShould you be buying NextCure stock or one of its competitors? The main competitors of NextCure include Skye Bioscience (SKYE), Tenaya Therapeutics (TNYA), Immix Biopharma (IMMX), OnKure Therapeutics (OKUR), Anebulo Pharmaceuticals (ANEB), Aadi Bioscience (AADI), Repare Therapeutics (RPTX), Cue Biopharma (CUE), Iterum Therapeutics (ITRM), and Actinium Pharmaceuticals (ATNM). These companies are all part of the "pharmaceutical products" industry. NextCure vs. Skye Bioscience Tenaya Therapeutics Immix Biopharma OnKure Therapeutics Anebulo Pharmaceuticals Aadi Bioscience Repare Therapeutics Cue Biopharma Iterum Therapeutics Actinium Pharmaceuticals Skye Bioscience (NASDAQ:SKYE) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, community ranking, analyst recommendations, earnings and valuation. Do analysts prefer SKYE or NXTC? Skye Bioscience currently has a consensus price target of $16.60, suggesting a potential upside of 950.63%. NextCure has a consensus price target of $3.50, suggesting a potential upside of 945.40%. Given Skye Bioscience's higher probable upside, analysts clearly believe Skye Bioscience is more favorable than NextCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Skye Bioscience 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00NextCure 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is SKYE or NXTC more profitable? Skye Bioscience's return on equity of -45.78% beat NextCure's return on equity.Company Net Margins Return on Equity Return on Assets Skye BioscienceN/A -45.78% -37.44% NextCure N/A -62.50%-53.67% Does the MarketBeat Community prefer SKYE or NXTC? NextCure received 68 more outperform votes than Skye Bioscience when rated by MarketBeat users. However, 100.00% of users gave Skye Bioscience an outperform vote while only 65.08% of users gave NextCure an outperform vote. CompanyUnderperformOutperformSkye BioscienceOutperform Votes14100.00% Underperform VotesNo VotesNextCureOutperform Votes8265.08% Underperform Votes4434.92% Which has preferable earnings & valuation, SKYE or NXTC? Skye Bioscience is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSkye BioscienceN/AN/A-$37.65M-$0.72-2.19NextCureN/AN/A-$62.72M-$1.98-0.17 Do institutionals and insiders hold more shares of SKYE or NXTC? 21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 3.0% of Skye Bioscience shares are held by insiders. Comparatively, 13.3% of NextCure shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more risk & volatility, SKYE or NXTC? Skye Bioscience has a beta of 1.88, indicating that its share price is 88% more volatile than the S&P 500. Comparatively, NextCure has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Does the media favor SKYE or NXTC? In the previous week, Skye Bioscience had 11 more articles in the media than NextCure. MarketBeat recorded 11 mentions for Skye Bioscience and 0 mentions for NextCure. NextCure's average media sentiment score of 1.89 beat Skye Bioscience's score of 0.25 indicating that NextCure is being referred to more favorably in the news media. Company Overall Sentiment Skye Bioscience Neutral NextCure Very Positive SummarySkye Bioscience beats NextCure on 9 of the 14 factors compared between the two stocks. Remove Ads Get NextCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NXTC vs. The Competition Export to ExcelMetricNextCurePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.38M$6.25B$5.28B$7.36BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-0.166.6921.6317.68Price / SalesN/A222.70371.0892.88Price / CashN/A65.6738.1534.64Price / Book0.085.776.373.94Net Income-$62.72M$142.01M$3.20B$247.45M7 Day Performance14.50%2.88%1.79%0.48%1 Month Performance-51.40%-13.93%-9.41%-7.08%1 Year Performance-79.59%-12.36%9.61%-0.35% NextCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NXTCNextCure4.5312 of 5 stars$0.33+0.6%$3.50+945.4%-80.1%$9.38MN/A-0.1690Gap DownHigh Trading VolumeSKYESkye Bioscience1.0272 of 5 stars$1.39+6.9%$18.00+1,195.0%-86.8%$43.06MN/A-1.9311Analyst RevisionNews CoverageGap DownTNYATenaya Therapeutics3.6259 of 5 stars$0.48-3.7%$6.25+1,201.8%-88.6%$42.05MN/A-0.33110Positive NewsGap DownHigh Trading VolumeIMMXImmix Biopharma2.9299 of 5 stars$1.51+0.7%$7.00+363.6%-36.8%$41.86MN/A-1.789OKUROnKure Therapeutics2.8826 of 5 stars$3.09-1.3%$32.33+946.4%N/A$41.52MN/A-0.25N/AGap DownHigh Trading VolumeANEBAnebulo Pharmaceuticals2.8124 of 5 stars$1.01-1.0%$8.00+692.1%-67.9%$41.50MN/A-3.614Short Interest ↓Positive NewsAADIAadi BioscienceN/A$1.66+1.2%$1.67+0.4%-10.0%$41.00M$25.07M-0.7340Gap DownRPTXRepare Therapeutics3.2775 of 5 stars$0.96-4.0%$4.50+368.9%-68.3%$40.80M$53.48M-0.48180Short Interest ↓News CoverageCUECue Biopharma4.3275 of 5 stars$0.63-7.3%$4.75+659.0%-49.8%$39.64M$9.53M-0.7060News CoverageGap DownITRMIterum Therapeutics1.6859 of 5 stars$1.11-1.8%$5.00+350.5%-27.3%$38.39MN/A-0.8510Gap DownATNMActinium Pharmaceuticals2.0034 of 5 stars$1.22-5.4%$7.40+506.6%N/A$38.06M$81,000.00-0.8830News CoverageGap Down Remove Ads Related Companies and Tools Related Companies SKYE Competitors TNYA Competitors IMMX Competitors OKUR Competitors ANEB Competitors AADI Competitors RPTX Competitors CUE Competitors ITRM Competitors ATNM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NXTC) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCould this be the start of AI’s Second Wind?We're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | SponsoredThis Crypto Is Set to Explode in JanuaryThe crypto summit Wall Street wants to stop Learn how to structure your portfolio like the top hedge funds...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NextCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NextCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NXTC Stock Free NXTC Stock Alerts